Abstract Number: 0584 • ACR Convergence 2020
Total Cost of Care for Patients with Rheumatoid Arthritis
Background/Purpose: The range of medical costs associated with rheumatoid arthritis (RA) is, in part, related to the various treatment options. Treatment for RA focuses on…Abstract Number: 0749 • ACR Convergence 2020
Locating Cellular Subsets in Rheumatoid Arthritis Synovium Using CO-Detection by IndEXing (CODEX)
Background/Purpose: To better understand site-of-disease mechanisms in arthritis, the phenotypes and organization of synovial cells and infiltrates are critical. Conventional histology-based approaches are limited in…Abstract Number: 0766 • ACR Convergence 2020
ACPA and Cholesterol Titers as Predictors of Good Clinical Response at One Year in an Argentine Cohort
Background/Purpose: Autoantibody positivity, erosions, activity level, and functional capacity were classically defined as poor prognosis. Paradoxically, many of them also predict a good response to…Abstract Number: 0783 • ACR Convergence 2020
Role of Glutamine Metabolism in Rheumatoid Arthritis Fibroblast-Like Synoviocyte Aggressive Phenotype
Background/Purpose: Fibroblast-like synoviocyte (FLS) activation is a key component of rheumatoid arthritis (RA) inflamed synovium. Their aggressive phenotype in RA contributes to initiation and perpetuation…Abstract Number: 0800 • ACR Convergence 2020
A Randomized, Double-Blind, Phase 3 Study to Compare the Efficacy and Safety of a Proposed High Concentration (100 mg/mL) Adalimumab Biosimilar (CT-P17) with Reference Adalimumab in Patients with Moderate-to-Severe Active Rheumatoid Arthritis
Background/Purpose: CT-P17 (100 mg/mL) is the first proposed biosimilar of the high concentration and citrate-free formulation of reference adalimumab. The purpose of this study was…Abstract Number: 0816 • ACR Convergence 2020
Treat-to-target Strategy in Patients with Rheumatoid Arthritis in Daily Clinical Practice -still Underused, but Superior to Routine Care: A Propensity Score Matched Analysis from the ATTRA Registry
Background/Purpose: Treat-to-target (T2T) is a widely accepted management strategy for RA. It recommends attaining a goal of at least low disease activity (LDA) within 6…Abstract Number: 0833 • ACR Convergence 2020
Optimized Treatment of Biological Disease Modifying Drugs in Routine Clinical Practice: Survival Study and Analysis of Patient Characteristics
Background/Purpose: The emergence of biological disease modifying drugs (bDMARD) has allowed a targeted approach to rheumatoid arthritis (RA) ("treat-to-treat" strategy). Once sustained remission is achieved,…Abstract Number: 0994 • ACR Convergence 2020
Does Tofacitinib Impact B Cell Functions?
Background/Purpose: Tofacitinib (tofa) inhibits cytokine signaling mediated by JAK1 JAK3 pathways leading therefore to a decrease in Th17 and an increase of Treg cells. The…Abstract Number: 1014 • ACR Convergence 2020
Disease Modifying Anti-rheumatic Drugs, Biologics and Corticosteroid Use in Older Patients with Rheumatoid Arthritis over 20 Years
Background/Purpose: The objective of the current study was to examine the change in prescribing patterns for older adults with RA over a 20 year period…Abstract Number: 1185 • ACR Convergence 2020
Performance of the MBDA-based CVD Risk Score in RA Patient Groups of Clinical Interest
Background/Purpose: A novel risk prediction score combines serum biomarkers from the multi-biomarker disease activity (MBDA) test with clinical information to predict 3-year risk for a…Abstract Number: 1201 • ACR Convergence 2020
Effect of Filgotinib on Pain in Patients with Rheumatoid Arthritis: Results from Phase 3 Clinical Trials
Background/Purpose: RA patients (pts) often suffer substantial pain despite ongoing treatment (tx) and regard pain control as a top tx goal. Filgotinib (FIL)—a potent, oral…Abstract Number: 1217 • ACR Convergence 2020
Effects of JAK Inhibitors Against JAK2-mediated Signaling in Innate Immune Cells
Background/Purpose: Janus kinase (JAK) family is comprised of JAK1, JAK2, JAK3 and tyrosine kinase 2 (TYK2). JAKs form homo- or hetero-complexes, the combination of which…Abstract Number: 1235 • ACR Convergence 2020
Radiographic Progression of Structural Joint Damage over 5 Years of Baricitinib Treatment in Patients with Rheumatoid Arthritis: Results from RA-BEYOND
Background/Purpose: Baricitinib (BARI) is an oral, reversible and selective Janus kinase 1 and 2 inhibitor. Treatment with once-daily oral BARI resulted in low rates of…Abstract Number: 1456 • ACR Convergence 2020
Exploring the RA Bone Marrow Niche by Single-cell Technology to Identify Long Lived ACPA+ Plasma Cells
Background/Purpose: Autoantibodies is a hallmark of rheumatoid arthritis, placing the adaptive immune system and B-cells centrally in the pathogenesis. The anti-citrullinated autoantibodies (ACPA) detected in…Abstract Number: 1534 • ACR Convergence 2020
Combined Thermal and Ultrasound Imaging in Rheumatoid Arthritis Is Superior to Either Imaging Alone in Terms of Correlation with the 28-joint Disease Activity Score
Background/Purpose: Combined thermal and ultrasound (US) imaging modalities in detecting joint inflammation in rheumatoid arthritis (RA) has not been evaluated relative to thermal or US…
- « Previous Page
- 1
- …
- 140
- 141
- 142
- 143
- 144
- …
- 188
- Next Page »